CTNNB1 and neoplasm: Matusda and colleagues designed an siRNA targeting CTNNB1 delivered within EVs.81 Using the Met/β-catenin mouse model (which represents ~ 10% of human HCC), they remarkably demonstrated that delivery of milk-derived EVs encapsulating siRNA to CTNNB1 (using transfection techniques) reduced tumor burden, in part through reversing the immunosuppressive tumor microenvironment driven by β-catenin, which allowed for synergy with ICIs.